A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.
Also called NCT02533453
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 110 participants
- Sponsor
- Registry
-
NCT02533453
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT02533453. Allocation not applicable; no masking; primary purpose treatment. Start 2016-01-28 (actual); primary completion 2016-12-07 (actual). Results posted on 2019-05-31.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.
- Acronym
- Bydureon
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Biological)
- Bydureon
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct02533453- Content hash
3e23d348d5d03d132e709964a83df05f69e342cf39335e56cf3744c562ac33f4